Home
ADC Summit 2013
20 May - 21 May 2013
ADC Summit 2013

SAE Media Group are pleased to announce their second annual ADC summit 2013. This event has a world leading speaking faculty that will provide the latest insights on antibody-drug conjugates.

Antibody drug conjugates are at the forefront of targeted chemotherapy for the treatment of cancer. Anticipated use of ADCs over the next 5-10 years in set to increase by 40-50% specifically within cancer research. This huge surge in programme is down to highly succesful clinical trials and results that indicate a leap forward in targeted therapeutic delivery, with monoclonal antibodies being used as a springboard for this huge success.

A unique event held in London, let ADC 2013 show you how and where the latest technologies and clinical data have transformed this field. Hear from recent advances in conjugate chemistry, target selection, novel payload deliveries, future ADC pipelines and regulatory issues.

The event will be presented via case studies by those who are working within the latest patents on new molecules. See the latest clinical data on ADCs pushing through trials in I-IV and methods to select antibody platforms that will be most effective against specific diseases.

FEATURED SPEAKERS

Alastair Lawson

Alastair Lawson

VP Structural Biology, UCB
John Hartley

John Hartley

Head of Biology, Spirogen
Kendall Morrison

Kendall Morrison

Director of Protein Technologies, Agensys (an affiliate of Astellas)
Robert Hollingsworth

Robert Hollingsworth

Senior Director, Medimmune Inc
Thomas  Pillow

Thomas Pillow

Scientist, Genentech

Alastair Lawson

VP Structural Biology, UCB
Alastair Lawson

Anna Butturini

Associate Medical Director, Agensys (an affiliate of Astellas)
Anna Butturini

Anthony Godwin

Director of Science & Technology, PolyTherics
Anthony Godwin

Daryl Drummond

Senior Director, Nanotherapeutics, Merrimack Pharmaceuticals
Daryl Drummond

Glen MacDonald

CSO, Viventia Bio Inc.
Glen MacDonald

Goncalo Bernardes

Principal Investigator & Royal Society University Research Fellow, Instituto de Medicina Molecular, Lisbon & Department of Chemistry, University of Cambridge
Goncalo Bernardes

John Hartley

Head of Biology, Spirogen
John Hartley

Katherine Vallis

Professor of Experimental Radiotherapeutics, University of Oxford
Katherine Vallis

Kendall Morrison

Director of Protein Technologies, Agensys (an affiliate of Astellas)
Kendall Morrison

Kerry Chester

Professor, University College London
Kerry Chester

Lutz Jermutus

Senior Director, Technology, MedImmune
Lutz Jermutus

Mahendra Deonarain

Honorary Reader in Antibody Technology , Imperial College London
Mahendra Deonarain

Matthias Machacek

Engineering Cluster Head, Novartis
Matthias Machacek

Natalie Thomas

Regulatory Affairs Project Manager, Era Consulting (UK) Limited
Natalie Thomas

Robert Hollingsworth

Senior Director, Medimmune Inc
Robert Hollingsworth

Thomas Pillow

Scientist, Genentech
Thomas  Pillow

Tony Maschio

Partner, Maschio & Soames LLP
Tony Maschio

Yulius Setiady

Principle Scientist, Discovery Research, Immunogen
Yulius Setiady

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Lutz Jermutus

Lutz Jermutus, Senior Director, Technology, MedImmune

clock

9:10

New opportunities for antibodies in enabling small molecule discovery

Alastair Lawson

Alastair Lawson, VP Structural Biology, UCB

  • Antibodies are successfully addressing modulation of protein-protein interactions in the clinic; enabling the discovery of small molecules "chemosuperiors"
  • Antibodiesare being used to define specific conformations of proteins providing new unexpected opportunities for intervention with small molecules
  • Small molecule fragment screening against antibody-constrained targets offers the prospect of discovering new chmical entities, the approach is well suited to small molecule discovery modulating protein-protein interactions
  • clock

    9:50

    Targeting solid tumors with Antibody-Directed Immunoliposomal Therapeutics

    Daryl Drummond

    Daryl Drummond, Senior Director, Nanotherapeutics, Merrimack Pharmaceuticals

  • Engineering considerations for development of targeted site-specific and sustained release of small molecule drugs
  • Contrast and complimentary strategy to standard ADC formats
  • Recent preclinical and clinical results
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Development of AGS15E, a novel antibody drug conjugate (using Monomethyl Auristatin E) Targeting SLITRK6 for the treatment of bladder cancer

    Kendall Morrison

    Kendall Morrison, Director of Protein Technologies, Agensys (an affiliate of Astellas)

  • Discovery and validation of SLITRK6 as a novel cancer target
  • Antibody discovery process
  • Pre-clinical evaluation and ADC development
  • clock

    11:40

    Building traceless Antibody-Drug Conjugates

    Goncalo Bernardes

    Goncalo Bernardes, Principal Investigator & Royal Society University Research Fellow, Instituto de Medicina Molecular, Lisbon & Department of Chemistry, University of Cambridge

  • Introductions
  • Site specific modification of traceless ADCs
  • Site specific modification of innovative ADCs
  • Case study
  • clock

    12:20

    Networking Lunch

    clock

    13:50

    Targeting tumor antigens with armed antibodies: Matching the tool to the job

    Robert Hollingsworth

    Robert Hollingsworth, Senior Director, Medimmune Inc

  • Identification and evaluation of tumor - associated antigens
  • Different armed antibody technologies used by MedImmune
  • Approaches to selecting the right armed antibody technology for individual tumor-associated antigens
  • clock

    14:30

    Antibody-Pyrrolobenzodiazepine (PBD) Conjugates

    John Hartley

    John Hartley, Head of Biology, Spirogen

  • Design and development of PBD-ADCs
  • Advantages of PBDs as ADC warheads
  • Case study and issues moving forward
  • clock

    15:10

    Afternoon Tea

    clock

    15:40

    Antibody-Directed Phototherapy (ADP) and Beyond

    Mahendra Deonarain

    Mahendra Deonarain, Honorary Reader in Antibody Technology , Imperial College London

  • Use of optimised antibody fragments
  • Light-activated and non-light activated drugs
  • Strategies for bio-conjugation
  • clock

    16:20

    Cancer testis antigens and other intranuclear targets for radioimmunotherapy

    Katherine Vallis

    Katherine Vallis, Professor of Experimental Radiotherapeutics, University of Oxford

  • Investigation of novel targets, including cancer testis antigens for radioimmunotherapy
  • Development of nano-scale microdosimetry systems for radioimmunotherapy
  • Case study
  • clock

    17:00

    Chairman’s Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Mahendra Deonarain

    Mahendra Deonarain, Honorary Reader in Antibody Technology , Imperial College London

    clock

    9:10

    Phase I clinical programme for the novel ADC AGS-16M8F/16C3F

    Anna Butturini

    Anna Butturini, Associate Medical Director, Agensys (an affiliate of Astellas)

  • Target selection - AGS-16 hits a single transmembrane antigen (EPP3 / CD203C ( ectonucleotide pyrophophatase/phosphodiesterase3))
  • AGS-16M8F/16C3F: IgG2 - Drug conjugate - Fully human from XenoMouse technology
  • Developing AGS-16M8F/16C3F - A unique antibody with significant preclinical activity in metastatic renal cell carcinoma
  • Case study phase I trial experience
  • clock

    9:50

    Ensuring a successful regulatory strategy to enable clinical development of ADCs: considerations for novel therapies and biobetters

    Natalie Thomas

    Natalie Thomas, Regulatory Affairs Project Manager, Era Consulting (UK) Limited

  • Regulatory requirements for commencement of clinical development of biobetters and novel ADCs
  • Strategic regulatory considerations for the development of ADCs
  • Case studies reviewing the successes and failures of ADCs to date, and lessons to be learned
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    DeBouganin: A next generation toxin payload for oncology

    Glen MacDonald

    Glen MacDonald, CSO, Viventia Bio Inc.

  • Review of the successful de-immunization of the plant cytotoxin Bouganin
  • Provide an overview of the advantages of deBouganin relative to other payload technologies
  • Comparative assessment of deBouganin vs. current ADC payloads
  • clock

    11:40

    Producing better antibody-drug conjugates using ThioBridge™ conjugation

    Anthony Godwin

    Anthony Godwin, Director of Science & Technology, PolyTherics

  • Efficient and predictable site-specific conjugation to disulfide bridges
  • Reduced heterogeneity as drug antibody ratio (DAR) limited to a maximum of 4
  • Ability to tailor the linker to the antibody and payload combination
  • In vitro and in vivo data for mAb and Fab confirms specific binding and activity
  • clock

    12:20

    Networking Lunch

    clock

    13:50

    Novel linker-drugs for ADCs

    Thomas  Pillow

    Thomas Pillow, Scientist, Genentech

  • Developing a linker-drug toolbox
  • Drugs with diverse mechanisms of action
  • Case study
  • clock

    14:30

    Discovery and preclinical evaluation of novel antibody-maytansinoid ADC product candidates

     

  • Rationale for target selection and strategies for target validation
  • Discovery and selection of optimal antibodies
  • Approaches for preclinical assessment of maytansinoid ADCs
  • Yulius Setiady

    Yulius Setiady, Principle Scientist, Discovery Research, Immunogen

    clock

    15:10

    Afternoon Tea

    clock

    15:40

    Panel Discussion: The future of ADCs

  • The most important factors moving forward
  • The latest improvements on current ADC research
  • Recent roadbloacks and challenges
  • Lutz Jermutus

    Lutz Jermutus, Senior Director, Technology, MedImmune

    Kerry Chester

    Kerry Chester, Professor, University College London

    clock

    16:30

    Intellectual property: colocation, synergy and ADCs

    Tony Maschio

    Tony Maschio, Partner, Maschio & Soames LLP

     

  • Are all antibody-drug conjugates obvious?
  • What is synergy?
  • Approaches to protecting ADCs
  • Strategies for attacking ADC patents
  • clock

    17:10

    Chairman’s Closing Remarks and Close of Day Two


    VP Structural Biology
    UCB
    Senior Director, Technology
    MedImmune
    Professor
    University College London
    Principal Investigator & Royal Society University Research Fellow
    Instituto de Medicina Molecular, Lisbon & Department of Chemistry, University of Cambridge
    Senior Director
    Medimmune Inc
    Head of Biology
    Spirogen
    Director of Science & Technology
    PolyTherics
    Scientist
    Genentech
    Senior Director, Nanotherapeutics
    Merrimack Pharmaceuticals
    Professor of Experimental Radiotherapeutics
    University of Oxford
    Principle Scientist, Discovery Research
    Immunogen
    Partner
    Maschio & Soames LLP
    Director of Protein Technologies
    Agensys (an affiliate of Astellas)
    Honorary Reader in Antibody Technology
    Imperial College London
    Engineering Cluster Head
    Novartis
    Associate Medical Director
    Agensys (an affiliate of Astellas)
    CSO
    Viventia Bio Inc.
    Regulatory Affairs Project Manager
    Era Consulting (UK) Limited

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.